STOCK TITAN

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

(Neutral)
(Neutral)
Tags

Vanda Pharmaceuticals (Nasdaq: VNDA) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 13, 2025, after market close. The company will host a conference call at 4:30 PM ET on the same day to discuss the financial results and other corporate activities.

Participants can join the conference call by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) using passcode 2881765. The call will be simultaneously broadcast and archived on Vanda's website. A replay will be available from 8:30 PM ET on February 13 until February 20, 2025, at 11:59 PM ET.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – VNDA

+3.53%
+3.53% Session move

In the trading session that priced this news, VNDA gained 3.53%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Conference Call and Webcast to Follow

WASHINGTON, Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2024 on Thursday, February 13, 2025, after the market closes.  

Vanda will host a conference call at 4:30 PM ET on Thursday, February 13, 2025, during which management will discuss the fourth quarter and full year 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 2881765.

The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, February 13, 2025, beginning at 8:30 PM ET and will be accessible until Thursday, February 20, 2025, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 2881765.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact:

Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer 
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2024-financial-results-on-february-13-2025-302369401.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

When will Vanda Pharmaceuticals (VNDA) release Q4 and full year 2024 earnings?

Vanda Pharmaceuticals will release its Q4 and full year 2024 financial results on Thursday, February 13, 2025, after market close.

How can investors access VNDA's Q4 2024 earnings conference call?

Investors can access the conference call by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) using passcode 2881765, or through the company's website at www.vandapharma.com.

What time is Vanda Pharmaceuticals' Q4 2024 earnings call?

Vanda Pharmaceuticals' Q4 2024 earnings conference call is scheduled for 4:30 PM ET on Thursday, February 13, 2025.

How long will VNDA's Q4 2024 earnings call replay be available?

The earnings call replay will be available from 8:30 PM ET on February 13 until 11:59 PM ET on February 20, 2025.